Cargando…
Confirming Multiplex RT-qPCR Use in COVID-19 with Next-Generation Sequencing: Strategies for Epidemiological Advantage
Rapid identification and tracking of emerging SARS-CoV-2 variants are critical for understanding the transmission dynamics and developing strategies for interrupting the transmission chain. Next-Generation Sequencing (NGS) is an exceptional tool for whole-genome analysis and deciphering new mutation...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339135/ https://www.ncbi.nlm.nih.gov/pubmed/35950011 http://dx.doi.org/10.1155/2022/2270965 |
_version_ | 1784760126399315968 |
---|---|
author | Carpenter, Rob E. Tamrakar, Vaibhav Chahar, Harendra Vine, Tyler Sharma, Rahul |
author_facet | Carpenter, Rob E. Tamrakar, Vaibhav Chahar, Harendra Vine, Tyler Sharma, Rahul |
author_sort | Carpenter, Rob E. |
collection | PubMed |
description | Rapid identification and tracking of emerging SARS-CoV-2 variants are critical for understanding the transmission dynamics and developing strategies for interrupting the transmission chain. Next-Generation Sequencing (NGS) is an exceptional tool for whole-genome analysis and deciphering new mutations. The technique has been instrumental in identifying the variants of concern (VOC) and tracking this pandemic. However, NGS is complex and expensive for large-scale adoption, and epidemiological monitoring with NGS alone could be unattainable in limited-resource settings. In this study, we explored the application of RT-qPCR-based detection of the variant identified by NGS. We analyzed a total of 78 deidentified samples that screened positive for SARS-CoV-2 from two timeframes, August 2020 and July 2021. All 78 samples were classified into WHO lineages by whole-genome sequencing and then compared with two commercially available RT-qPCR assays for spike protein mutation(s). The data showed good concordance between RT-qPCR and NGS analysis for specific SARS-CoV-2 lineages and characteristic mutations. RT-qPCR assays are quick and cost-effective and thus can be implemented in synergy with NGS for screening NGS-identified mutations of SARS-CoV-2 for clinical and epidemiological interest. Strategic use of NGS and RT-qPCR can offer several COVID-19 epidemiological advantages. |
format | Online Article Text |
id | pubmed-9339135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-93391352022-08-09 Confirming Multiplex RT-qPCR Use in COVID-19 with Next-Generation Sequencing: Strategies for Epidemiological Advantage Carpenter, Rob E. Tamrakar, Vaibhav Chahar, Harendra Vine, Tyler Sharma, Rahul Glob Health Epidemiol Genom Research Article Rapid identification and tracking of emerging SARS-CoV-2 variants are critical for understanding the transmission dynamics and developing strategies for interrupting the transmission chain. Next-Generation Sequencing (NGS) is an exceptional tool for whole-genome analysis and deciphering new mutations. The technique has been instrumental in identifying the variants of concern (VOC) and tracking this pandemic. However, NGS is complex and expensive for large-scale adoption, and epidemiological monitoring with NGS alone could be unattainable in limited-resource settings. In this study, we explored the application of RT-qPCR-based detection of the variant identified by NGS. We analyzed a total of 78 deidentified samples that screened positive for SARS-CoV-2 from two timeframes, August 2020 and July 2021. All 78 samples were classified into WHO lineages by whole-genome sequencing and then compared with two commercially available RT-qPCR assays for spike protein mutation(s). The data showed good concordance between RT-qPCR and NGS analysis for specific SARS-CoV-2 lineages and characteristic mutations. RT-qPCR assays are quick and cost-effective and thus can be implemented in synergy with NGS for screening NGS-identified mutations of SARS-CoV-2 for clinical and epidemiological interest. Strategic use of NGS and RT-qPCR can offer several COVID-19 epidemiological advantages. Hindawi 2022-07-30 /pmc/articles/PMC9339135/ /pubmed/35950011 http://dx.doi.org/10.1155/2022/2270965 Text en Copyright © 2022 Rob E. Carpenter et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Carpenter, Rob E. Tamrakar, Vaibhav Chahar, Harendra Vine, Tyler Sharma, Rahul Confirming Multiplex RT-qPCR Use in COVID-19 with Next-Generation Sequencing: Strategies for Epidemiological Advantage |
title | Confirming Multiplex RT-qPCR Use in COVID-19 with Next-Generation Sequencing: Strategies for Epidemiological Advantage |
title_full | Confirming Multiplex RT-qPCR Use in COVID-19 with Next-Generation Sequencing: Strategies for Epidemiological Advantage |
title_fullStr | Confirming Multiplex RT-qPCR Use in COVID-19 with Next-Generation Sequencing: Strategies for Epidemiological Advantage |
title_full_unstemmed | Confirming Multiplex RT-qPCR Use in COVID-19 with Next-Generation Sequencing: Strategies for Epidemiological Advantage |
title_short | Confirming Multiplex RT-qPCR Use in COVID-19 with Next-Generation Sequencing: Strategies for Epidemiological Advantage |
title_sort | confirming multiplex rt-qpcr use in covid-19 with next-generation sequencing: strategies for epidemiological advantage |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339135/ https://www.ncbi.nlm.nih.gov/pubmed/35950011 http://dx.doi.org/10.1155/2022/2270965 |
work_keys_str_mv | AT carpenterrobe confirmingmultiplexrtqpcruseincovid19withnextgenerationsequencingstrategiesforepidemiologicaladvantage AT tamrakarvaibhav confirmingmultiplexrtqpcruseincovid19withnextgenerationsequencingstrategiesforepidemiologicaladvantage AT chaharharendra confirmingmultiplexrtqpcruseincovid19withnextgenerationsequencingstrategiesforepidemiologicaladvantage AT vinetyler confirmingmultiplexrtqpcruseincovid19withnextgenerationsequencingstrategiesforepidemiologicaladvantage AT sharmarahul confirmingmultiplexrtqpcruseincovid19withnextgenerationsequencingstrategiesforepidemiologicaladvantage |